{"doc_id": "32896292", "type of study": "Therapy", "title": "", "abstract": "Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.\nThe efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain.\nWe assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.\nWe did an open-label, randomised clinical trial at 57 centres in Brazil.\nWe enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation.\nPatients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care or to standard of care without macrolides.\nAll patients received hydroxychloroquine (400 mg twice daily for 10 days) because that was part of standard of care treatment in Brazil for patients with severe COVID-19.\nThe primary outcome, assessed by an independent adjudication committee masked to treatment allocation, was clinical status at day 15 after randomisation, assessed by a six-point ordinal scale, with levels ranging from 1 to 6 and higher scores indicating a worse condition (with odds ratio [OR] greater than 1\u00b700 favouring the control group).\nThe primary outcome was assessed in all patients in the intention-to-treat (ITT) population who had severe acute respiratory syndrome coronavirus 2 infection confirmed by molecular or serological testing before randomisation (ie, modified ITT [mITT] population).\nSafety was assessed in all patients according to which treatment they received, regardless of original group assignment.\nThis trial was registered at ClinicalTrials.gov, NCT04321278.\n447 patients were enrolled from March 28 to May 19, 2020.\nCOVID-19 was confirmed in 397 patients who constituted the mITT population, of whom 214 were assigned to the azithromycin group and 183 to the control group.\nIn the mITT population, the primary endpoint was not significantly different between the azithromycin and control groups (OR 1\u00b736 [95% CI 0\u00b794-1\u00b797], p=0\u00b711).\nRates of adverse events, including clinically relevant ventricular arrhythmias, resuscitated cardiac arrest, acute kidney failure, and corrected QT interval prolongation, were not significantly different between groups.\nIn patients with severe COVID-19, adding azithromycin to standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes.\nOur findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19.\nCOALITION COVID-19 Brazil and EMS.\nCopyright \u00a9 2020 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "admitted to the hospital", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 128}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 149}, {"term": "admitted to the hospital", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 166}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 41}, {"term": "suspected or confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 78}, {"term": "oxygen supplementation of more than 4", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 182}, {"term": "min flow", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 195}, {"term": "severe acute respiratory syndrome coronavirus 2 infection", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 159}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 32}, {"term": "severe COVID-19", "negation": "negated", "UMLS": {}, "start": 116, "end": 131}, {"term": "EMS", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 33}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil ( COALITION II ) : a randomised clinical trial .", "Evidence Elements": {"Participant": [{"term": "admitted to the hospital", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 128}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 149}], "Intervention": [{"term": "Azithromycin in addition to standard of care", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 44, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 0, "end": 12}], "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 28, "end": 44}], "has_relation": "combined_with (C0812732<->C2936643)"}, {"term": "standard of care alone", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 74, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 16}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We assessed whether adding azithromycin to standard of care , which included hydroxychloroquine , would improve clinical outcomes of patients admitted to the hospital with severe COVID-19 .", "Evidence Elements": {"Participant": [{"term": "admitted to the hospital", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 166}], "Intervention": [{"term": "adding azithromycin to standard of care", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 59, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 7, "end": 19}], "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 23, "end": 39}], "has_relation": "combined_with (C0812732<->C2936643)"}], "Outcome": [{"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 129}], "Observation": [{"term": "improve", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 111}], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We did an open-label , randomised clinical trial at 57 centres in Brazil .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows : use of oxygen supplementation of more than 4 L / min flow ; use of high-flow nasal cannula ; use of non-invasive mechanical ventilation ; or use of invasive mechanical ventilation .", "Evidence Elements": {"Participant": [{"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 41}, {"term": "suspected or confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 78}, {"term": "oxygen supplementation of more than 4", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 182}, {"term": "min flow", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 195}], "Intervention": [{"term": "high-flow nasal cannula", "negation": "affirmed", "UMLS": {}, "start": 205, "end": 228, "has_device": [{"text": "high flow nasal cannula", "maps_to": "C0179574:nasal cannula", "start": 0, "end": 23}], "has_relation": "N/A"}, {"term": "non-invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 238, "end": 273, "has_procedure": [{"text": "non invasive mechanical ventilation", "maps_to": "C2349740:Non-invasive mechanical ventilation", "start": 0, "end": 35}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned (1:1) to azithromycin ( 500 mg via oral , nasogastric , or intravenous administration once daily for 10 days ) plus standard of care or to standard of care without macrolides .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 53, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "plus standard of care", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 164, "has_procedure": [{"text": "standard of care", "maps_to": "C2936643:standard of care", "start": 5, "end": 21}], "has_relation": "N/A"}, {"term": "standard", "negation": "affirmed", "UMLS": {}, "start": 148, "end": 156, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "All patients received hydroxychloroquine ( 400 mg twice daily for 10 days ) because that was part of standard of care treatment in Brazil for patients with severe COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 40, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome , assessed by an independent adjudication committee masked to treatment allocation , was clinical status at day 15 after randomisation , assessed by a six-point ordinal scale , with levels ranging from 1 to 6 and higher scores indicating a worse condition ( with odds ratio [ OR ] greater than 1\u00b700 favouring the control group ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "clinical status", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 124}, {"term": "worse condition", "negation": "affirmed", "UMLS": {}, "start": 260, "end": 275}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was assessed in all patients in the intention-to-treat ( ITT ) population who had severe acute respiratory syndrome coronavirus 2 infection confirmed by molecular or serological testing before randomisation ( ie , modified ITT [ mITT ] population ) .", "Evidence Elements": {"Participant": [{"term": "severe acute respiratory syndrome coronavirus 2 infection", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 159}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Safety was assessed in all patients according to which treatment they received , regardless of original group assignment .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "original group", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 109, "has_relation": "N/A"}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This trial was registered at ClinicalTrials.gov , NCT04321278 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "447 patients were enrolled from March 28 to May 19 , 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "COVID-19 was confirmed in 397 patients who constituted the mITT population , of whom 214 were assigned to the azithromycin group and 183 to the control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "azithromycin", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 122, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 151, "has_relation": "N/A"}], "Outcome": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 8}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "In the mITT population , the primary endpoint was not significantly different between the azithromycin and control groups ( OR 1\u00b736 [ 95 % CI 0\u00b794-1\u00b797 ] , p=0\u00b711 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "azithromycin", "negation": "negated", "UMLS": {}, "start": 90, "end": 102, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "negation": "negated", "UMLS": {}, "start": 107, "end": 114, "has_relation": "N/A"}], "Outcome": [{"term": "primary endpoint", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 45}], "Observation": [{"term": "significantly different", "negation": "negated", "UMLS": {}, "start": 54, "end": 77}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "azithromycin", "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "has_relation": "N/A"}], "Observation": "significantly different", "Outcome": "primary endpoint", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Rates of adverse events , including clinically relevant ventricular arrhythmias , resuscitated cardiac arrest , acute kidney failure , and corrected QT interval prolongation , were not significantly different between groups .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Rates of adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23}, {"term": "clinically relevant ventricular arrhythmias", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 79}, {"term": "resuscitated cardiac arrest", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 109}, {"term": "acute kidney failure", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 132}, {"term": "corrected QT interval prolongation", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 173}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "In patients with severe COVID-19 , adding azithromycin to standard of care treatment ( which included hydroxychloroquine ) did not improve clinical outcomes .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 32}], "Intervention": [{"term": "adding azithromycin to standard of care treatment", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 84, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 7, "end": 19}], "has_procedure": [{"text": "standard of care treatment", "maps_to": "C0087111:treatment", "start": 23, "end": 49}], "has_relation": "combined_with (C0812732<->C0087111)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Our findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19 .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "negated", "UMLS": {}, "start": 116, "end": 131}], "Intervention": [{"term": "azithromycin in combination with hydroxychloroquine", "negation": "negated", "UMLS": {}, "start": 47, "end": 98, "has_drug": [{"text": "azithromycin", "maps_to": "C0812732:Azithromycin", "start": 0, "end": 12}], "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 33, "end": 51}], "has_relation": "combined_with (C0812732<->C0020336)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "COALITION COVID-19 Brazil and EMS .", "Evidence Elements": {"Participant": [{"term": "EMS", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 33}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}